LIVE POLIO IRUS VACCINES

Index
631
Vaccination-continued
reports, 486
seronegative indices before and after, 367
"takes," complexities of achieving 100%, 183
transient protection against enterovirtus infection,
154
Vaccine-associated cases
a case with residual symptoms, 465
criteria for designating, 457
18 cases of vaccinated children in Mexico City,
397-398
5 paralytic polio cases within two weeks of ingestion,
455
5 polio cases observed in vaccinees, 453
14 polio cases among vaccinated, clinical histories,
570-573
Massachusetts, incident, 1959, 374
reported cases of paralytic polio, 553
7 children hospitalized and one death after vaccination,
279
studies on 17 cases in Guadalajara, 398
39 cases of polio in vaccinated individuals, Leopoldville,
Congo, 469
32 vaccinees diagnosed as polio, Karaganda SSR.
464
27 cases in vaccinees, 553-558
United States, incident, 1960, 373
Vaccine, Attenuated
choice of strains
capsule vs. fluid administration, 357, 368, 416
properties of strains, 40, 109, 600
requirements, listed, 7, 77, 97, 117, 124, 192, 199.
341, 414, 579
search for better Type 3 strain indicated, 58
selection, 190
strains listed (table), 124
control and production
in continuous line cells, 599
preparation technique, South Africa, USSR, 505
purification, considered, 87
rigorous safety tests, 8
simian viruses, exclusion, 79
storage, 193, 208, 418
variation among lots, 12, 532
developmental
cold mutant study, 101
elution study, 44-45
laboratory investigations, 68-78, 90-97, 124-131
marker evaluation of safety, 46, 53-65
markers serve dual purpose, 47
reproducibility in neurovirulence tests, 12, 18,
26, 77
role of First Conference, 3
virulence following IM inoculation and sciatic
nerve injury, 94
viruilent T+ mutant, 480
feeding and dosage
administration rate, 437-438
after Salk vaccine, 187
asymptomatic feeding, 5
bivalent feeding error, 348
combined with DPT, 328
distribution data, 422, 559, 583
feeding and dosage-continued
dose and administration, 68, 144, 193, 216, 277,
309, 315-316, 330, 338, 357, 365, 368, 401,
419, 437-438, 478, 485, 489, 507, 522, 541,
563, 575, 583 -
feeding technique, babies, 309
in endemic areas, 385
infants, 218, 287-293, 308-314, 315-321
injected subcutaneously, 526
low cost, 576
need for booster, 603
optimum administration during cold months, 385,
437
organization, 338, 420, 568, 594
waste, 15-20% during campaign, 582
results and evaluation
advantages of live over inactivated, 3, 191, 519,
532, 579
analysis of non-specific factors, 268
benefits given to population, 4
capacity to produce antibody, 430
changes after multiplication in man, 12-26, 29
characteristics, before and after immunization, 600
convenience, 497
efficacy, 113-120, 206, 281, 283, 313, 348, 411,
444, 493, 512, 559, 568, 576-577, 579, 602
evaluation, 238, 371, 458, 486, 520, 531, 568, 576
extermination of wild virus, 482
failure, 557
field trials in areas of ultimate utilization, 444
heterotypic protection, 6
illnesses, 278, 282, 345
infectability, theoretical schema, 174
magnitude of studies, 3
mutants hamper interpretation, 110
polio not caused by, 136, 454, 573, 593
program, practical public health measure, 277
response, 225, 336, 339, 445, 571, 573
safety, 6-7, 27, 47, 120, 141, 454, 462-463, 474.
507, 576-577, 584
spectrum of virulence, 109
tin anniversary, 5-9
spread
contact infection following Coxsackie, 157
criteria, 117
establishment, 243, 246, 484, 557
excretion, 114, 133, 171, 243, 245, 523
invasive properties, 94
no increase of virulence, 161
persistence under field conditions, 431, 517
recovery in pharyngeal excretion, 341-354
reinfection data, 123, 325
reversion to virulence, 152
spread, 7, 29, 152, 163, 172, 381, 518, 542
Type 1, CHAT (Koprowski)
African children vaccinated, 466
and contact spread, 188
antigenic stability, 54, 66
elution study, 42
fed infants, 287
field and laboratory experiences, 187-190
markers of original and progeny, 470
not used after consideration, 475, 479